Adhera Therapeutics Inc (ATRX): $ATRX Adhera to develop MLR-1023 as a ne...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: None

Thursday, 09/30/2021 11:34:20 AM

Thursday, September 30, 2021 11:34:20 AM

$ATRX Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)

Keep Last Read

Next 10 Prev Next

Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 01/30/2024 09:00:03 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:25:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:01:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:51:55 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:35:43 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:58:43 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 07:32:22 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:05:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 08:54:24 PM

InvestorsHub NewsWire

Only $200 per official company press release!